AlloVir, Inc. (ALVR)
NASDAQ: ALVR · Real-Time Price · USD
0.930
+0.044 (4.97%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.

The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.

The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.

The company was incorporated in 2013 and is based in Waltham, Massachusetts.

AlloVir, Inc.
AlloVir logo
Country United States
Founded 2013
IPO Date Jul 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 112
CEO Diana Brainard

Contact Details

Address:
1100 Winter Street
Waltham, Massachusetts 02451
United States
Phone 617 433 2605
Website allovir.com

Stock Details

Ticker Symbol ALVR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001754068
CUSIP Number 019818103
ISIN Number US0198181036
Employer ID 83-1971007
SIC Code 2836

Key Executives

Name Position
Dr. Diana M. Brainard M.D. Chief Executive Officer and Director
David L. Hallal Executive Chairman of the Board
Vikas Sinha C.A., CPA, M.B.A. President, Chief Financial Officer and Director
Edward Miller J.D. General Counsel and Secretary
Brett R. Hagen Chief Accounting Officer
Dr. Ann M. Leen Ph.D. Chief Scientific Officer
Cintia Piccina Pharm.D. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 22, 2024 144 Filing
Oct 22, 2024 144 Filing
Oct 22, 2024 144 Filing
Oct 21, 2024 144 Filing
Oct 21, 2024 144 Filing
Oct 21, 2024 144 Filing
Oct 21, 2024 144 Filing
Oct 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 3, 2024 144 Filing
Oct 3, 2024 144 Filing